-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article was originally written by Translational Medicine.
Please indicate the source Author: Daisy Introduction: In the past year and a half, the SARS-CoV-2 virus has infected 261 million people and caused more than 5 million deaths (WHO.
org)
.
Although a vaccine against SARS-CoV-2 has been rapidly developed, antiviral therapies are still lacking
.
The urgent need for treatments is magnified by the emerging threat of variants that could evade vaccines
.
A large-scale effort is currently underway to identify antiviral drugs, with approximately 18,000 drugs screened for antiviral activity using live viral infection in human respiratory cells, and 122 validated for antiviral activity against SARS-CoV-2 and selective drugs
.
Among these drug candidates are 16 nucleoside analogs, including remdesivir and molnupiravir, which have been approved for COVID-19
.
RNA viruses rely on a large number of nucleoside triphosphates in the host for efficient replication, and the researchers identified inhibitors of host nucleoside biosynthesis as antiviral drugs
.
In addition, the combination of pyrimidine biosynthesis inhibitors and antiviral nucleoside analogs was found to synergistically inhibit SARS-CoV-2 infection in vitro and in vivo against emerging SARS-CoV-2 strains, suggesting a clinical way forward
.
Researchers have discovered a powerful combination of antiviral drugs to treat COVID-19
.
Combining the drug Brequniar with remdesivir or molnupirvir, both of which have been approved for emergency use by the U.
S.
Food and Drug Administration, inhibited SARS-CoV-2 in human respiratory cells and in mice 2 viruses, according to a new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and the University of Maryland School of Medicine
.
The findings, published this week in the journal Nature, show that these drugs are more effective in combination than they are alone, according to an article titled "Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2": https: // Although the drugs have not been tested in clinical trials, the drugs identified in their study The drug combination has the potential to be a very promising treatment for COVID-19
.
Dr.
Sara Cherry co-led the research with Dr.
David Schultz, technical director of the Penn High Throughput Screening Core
.
The researchers also included Matthew Frieman, PhD, of the Pathogen Research Center at the University of Maryland School of Medicine, and collaborators from the National Institutes of Health
.
"Determining the combination of antiviral drugs is really important, not only because doing so may increase the drug's efficacy against the coronavirus, but the combination also reduces the risk of resistance," Dr.
Cherry
said
.
The new coronavirus SARS-CoV-2 has infected 382 million people and caused 5 million deaths worldwide
.
There is still an urgent need for treatments to treat COVID-19, compounded by the emerging threat of mutations that could evade vaccines
.
To address this need, Dr.
Cherry and his collaborating team screened 18,000 drugs for antiviral activity using live SARS-CoV-2 infection in human respiratory epithelial cells, since lung cells are the primary target of the virus
.
The researchers identified 122 drugs that showed antiviral activity and selectivity against the coronavirus, including 16 nucleoside analogs, the largest class of antiviral drugs in clinical use
.
Of the 16 drugs, remdesivir and molnupiravir (an oral pill, approved for use in December) are listed as treatments for Covid-19
.
Remdesivir is an intravenous drug that has been approved by the FDA for the treatment of COVID-19
.
Also among the 122 drug candidates, the researchers identified a panel of host nucleoside biosynthesis inhibitors, including the experimental drug brequinar
.
Nucleoside biosynthesis inhibitors work by preventing the body's own enzymes from making nucleosides, thereby preventing viruses from "stealing" RNA building blocks and replicating
.
Brequinar is currently in clinical trials as a COVID-19 therapy and as part of a potential combination therapy for some cancers
.
Cherry and collaborators hypothesized that combining brequinar with a nucleoside analog, such as remdesivir or molnupiravir, would work "synergistically" to produce a stronger effect on the virus
.
Synergy occurs when the combined effect of two or more drugs is greater than the sum of the effects of each drug individually
.
If remdesivir is simply combined with molnupiravir, there will be no "1+1>2" effect
.
"We thought that using these nucleoside analogs, while also reducing the levels of the host nucleoside building blocks, might work together to super destroy the virus," said Dr Cherry.
"Surprisingly, when you combine them in Together, the virus completely died
.
" The researchers tested the drugs on lung cells and mice and found that the combinations were highly effective against multiple strains of the coronavirus, including the Delta variant
.
The team is currently drug testing Omicron
.
In addition, the researchers found that the oral antiviral drug Paxlovid was also recently approved by the FDA for use in combination with remdesivir or molnupiravir for an "additional" effect against SARS-CoV-2
.
The next step will be clinical trials of these drug combinations
.
"As new strains of the virus emerge, the need for new treatments remains acute," said Frieman, co-principal investigator of the study
.
"
We now know that there are many powerful drug combinations that have the potential to alter the virus' trajectory
.
" References: https://medicalxpress.
com/news/2022-02-antiviral-drug-combination-highly-effective.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Event The first Yangtze River Delta single-cell omics technology application forum "Drug Precision" series of live broadcasts: the second phase of MRD detection and Car-T cell therapy development popular articles Organoid research [year-end inventory] must-see in the field of organoids in 2021 Essential Research Content Medical Research [Cell Sub-Journal] Optimization Technology! Restore human cells to stem cell state! Cancer Research [Science Sub-Journal] Will "lactic acid" help cancer cells? Studies have found that specific enzymes can fight it! Genetic Testing【Science Sub-Journal】A previously unknown gene mutation, BAG5, can cause incurable heart disease cancer research 【Science Sub-Journal】“Pseudogene” carcinogenic? Research identifies a new pathway leading to liver cancer -- pseudogene demethylation, which could help develop new treatments! New research shows how to test the effectiveness of anti-cancer drugs
Please indicate the source Author: Daisy Introduction: In the past year and a half, the SARS-CoV-2 virus has infected 261 million people and caused more than 5 million deaths (WHO.
org)
.
Although a vaccine against SARS-CoV-2 has been rapidly developed, antiviral therapies are still lacking
.
The urgent need for treatments is magnified by the emerging threat of variants that could evade vaccines
.
A large-scale effort is currently underway to identify antiviral drugs, with approximately 18,000 drugs screened for antiviral activity using live viral infection in human respiratory cells, and 122 validated for antiviral activity against SARS-CoV-2 and selective drugs
.
Among these drug candidates are 16 nucleoside analogs, including remdesivir and molnupiravir, which have been approved for COVID-19
.
RNA viruses rely on a large number of nucleoside triphosphates in the host for efficient replication, and the researchers identified inhibitors of host nucleoside biosynthesis as antiviral drugs
.
In addition, the combination of pyrimidine biosynthesis inhibitors and antiviral nucleoside analogs was found to synergistically inhibit SARS-CoV-2 infection in vitro and in vivo against emerging SARS-CoV-2 strains, suggesting a clinical way forward
.
Researchers have discovered a powerful combination of antiviral drugs to treat COVID-19
.
Combining the drug Brequniar with remdesivir or molnupirvir, both of which have been approved for emergency use by the U.
S.
Food and Drug Administration, inhibited SARS-CoV-2 in human respiratory cells and in mice 2 viruses, according to a new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and the University of Maryland School of Medicine
.
The findings, published this week in the journal Nature, show that these drugs are more effective in combination than they are alone, according to an article titled "Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2": https: // Although the drugs have not been tested in clinical trials, the drugs identified in their study The drug combination has the potential to be a very promising treatment for COVID-19
.
Dr.
Sara Cherry co-led the research with Dr.
David Schultz, technical director of the Penn High Throughput Screening Core
.
The researchers also included Matthew Frieman, PhD, of the Pathogen Research Center at the University of Maryland School of Medicine, and collaborators from the National Institutes of Health
.
"Determining the combination of antiviral drugs is really important, not only because doing so may increase the drug's efficacy against the coronavirus, but the combination also reduces the risk of resistance," Dr.
Cherry
said
.
The new coronavirus SARS-CoV-2 has infected 382 million people and caused 5 million deaths worldwide
.
There is still an urgent need for treatments to treat COVID-19, compounded by the emerging threat of mutations that could evade vaccines
.
To address this need, Dr.
Cherry and his collaborating team screened 18,000 drugs for antiviral activity using live SARS-CoV-2 infection in human respiratory epithelial cells, since lung cells are the primary target of the virus
.
The researchers identified 122 drugs that showed antiviral activity and selectivity against the coronavirus, including 16 nucleoside analogs, the largest class of antiviral drugs in clinical use
.
Of the 16 drugs, remdesivir and molnupiravir (an oral pill, approved for use in December) are listed as treatments for Covid-19
.
Remdesivir is an intravenous drug that has been approved by the FDA for the treatment of COVID-19
.
Also among the 122 drug candidates, the researchers identified a panel of host nucleoside biosynthesis inhibitors, including the experimental drug brequinar
.
Nucleoside biosynthesis inhibitors work by preventing the body's own enzymes from making nucleosides, thereby preventing viruses from "stealing" RNA building blocks and replicating
.
Brequinar is currently in clinical trials as a COVID-19 therapy and as part of a potential combination therapy for some cancers
.
Cherry and collaborators hypothesized that combining brequinar with a nucleoside analog, such as remdesivir or molnupiravir, would work "synergistically" to produce a stronger effect on the virus
.
Synergy occurs when the combined effect of two or more drugs is greater than the sum of the effects of each drug individually
.
If remdesivir is simply combined with molnupiravir, there will be no "1+1>2" effect
.
"We thought that using these nucleoside analogs, while also reducing the levels of the host nucleoside building blocks, might work together to super destroy the virus," said Dr Cherry.
"Surprisingly, when you combine them in Together, the virus completely died
.
" The researchers tested the drugs on lung cells and mice and found that the combinations were highly effective against multiple strains of the coronavirus, including the Delta variant
.
The team is currently drug testing Omicron
.
In addition, the researchers found that the oral antiviral drug Paxlovid was also recently approved by the FDA for use in combination with remdesivir or molnupiravir for an "additional" effect against SARS-CoV-2
.
The next step will be clinical trials of these drug combinations
.
"As new strains of the virus emerge, the need for new treatments remains acute," said Frieman, co-principal investigator of the study
.
"
We now know that there are many powerful drug combinations that have the potential to alter the virus' trajectory
.
" References: https://medicalxpress.
com/news/2022-02-antiviral-drug-combination-highly-effective.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Event The first Yangtze River Delta single-cell omics technology application forum "Drug Precision" series of live broadcasts: the second phase of MRD detection and Car-T cell therapy development popular articles Organoid research [year-end inventory] must-see in the field of organoids in 2021 Essential Research Content Medical Research [Cell Sub-Journal] Optimization Technology! Restore human cells to stem cell state! Cancer Research [Science Sub-Journal] Will "lactic acid" help cancer cells? Studies have found that specific enzymes can fight it! Genetic Testing【Science Sub-Journal】A previously unknown gene mutation, BAG5, can cause incurable heart disease cancer research 【Science Sub-Journal】“Pseudogene” carcinogenic? Research identifies a new pathway leading to liver cancer -- pseudogene demethylation, which could help develop new treatments! New research shows how to test the effectiveness of anti-cancer drugs
